Outsourcing Drivers By Company Size

In Q4 2018, ISR surveyed 121 outsourcers of large molecule drug substance manufacturing to understand their primary reason for working with CMOs for biologic API. The data show respondents from small companies, with an annual R&D spend under $1B, are more likely to use CMOs for all of their manufacturing needs than respondents from large pharma companies (61% vs 24%). Conversely, respondents from large pharma companies are more likely to use CMOs to augment their internal manufacturing capacity (57% vs 31%) and to access additional markets (15% vs 2%).